{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=36", "query": { "condition": "Metastatic Solid Cancer", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1764, "total_pages": 177, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:42:32.043Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06228326", "title": "A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer, Non-small Cell", "Lung Cancer Metastatic", "Solid Tumor, Adult", "Advanced Cancer", "Lung Cancer (NSCLC)" ], "interventions": [ { "name": "KB707", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Krystal Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-04-17", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 14, "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 11 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06228326" }, { "nct_id": "NCT00019578", "title": "Stereotactic Radiosurgery in Treating Patients With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Central Nervous System Germ Cell Tumor", "Adult Malignant Meningioma", "Adult Medulloblastoma", "Adult Noninfiltrating Astrocytoma", "Adult Oligodendroglioma", "Adult Craniopharyngioma", "Adult Meningioma", "Brain Metastases", "Adult Ependymoma", "Adult Pineal Parenchymal Tumor", "Adult Brain Stem Glioma", "Adult Infiltrating Astrocytoma", "Mixed Gliomas", "Stage IV Peripheral Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "Sterotactic radiosurgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": "2002-05", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019578" }, { "nct_id": "NCT03435952", "title": "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm of Breast", "Malignant Neoplasms of Digestive Organs", "Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites", "Malignant Neoplasms of Independent (Primary) Multiple Sites", "Malignant Neoplasms of Lip Oral Cavity and Pharynx", "Malignant Neoplasms of Male Genital Organs", "Malignant Neoplasms of Mesothelial and Soft Tissue", "Malignant Neoplasms of Respiratory and Intrathoracic Organs", "Malignant Neoplasms of Thyroid and Other Endocrine Glands", "Malignant Neoplasms of Urinary Tract" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Clostridium Novyi-NT", "type": "BIOLOGICAL" }, { "name": "Doxycycline", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-07-10", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435952" }, { "nct_id": "NCT03785249", "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2019-01-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 221, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03785249" }, { "nct_id": "NCT05346484", "title": "A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Cholangiocarcinoma", "Bile Duct Cancer" ], "interventions": [ { "name": "CF33-hNIS", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Modified FOLFOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Imugene Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-05-17", "completion_date": "2026-01-12", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 10, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346484" }, { "nct_id": "NCT04111458", "title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, KRAS Mutation; SOS1" ], "interventions": [ { "name": "BI 1701963", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2019-11-04", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111458" }, { "nct_id": "NCT02715284", "title": "Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 729, "start_date": "2016-03-07", "completion_date": "2028-04-14", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715284" }, { "nct_id": "NCT02223052", "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Neoplasms", "Non-Hodgkin's Lymphoma", "Hodgkin's Lymphoma", "Lymphoma", "Multiple Myeloma", "Acute Myeloid Leukemia", "Leukemia", "Myelodysplastic Syndromes", "Neoplasms", "Melanoma", "Breast Cancer", "Metastatic Breast Cancer", "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Glioblastoma Multiforme", "Osteosarcoma", "Sarcoma", "Thyroid Cancer", "Genitourinary" ], "interventions": [ { "name": "CC-486", "type": "DRUG" }, { "name": "Vidaza", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2014-10-27", "completion_date": "2018-12-18", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02223052" }, { "nct_id": "NCT05082610", "title": "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Tumor, Solid", "Nonsmall Cell Lung Cancer", "Triple Negative Breast Cancer", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "HMBD-002", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hummingbird Bioscience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-02-28", "completion_date": "2024-12-03", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 6, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05082610" }, { "nct_id": "NCT05639751", "title": "PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Non-small Cell Lung Cancers", "SMARCA4 Gene Mutation" ], "interventions": [ { "name": "PRT3789", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2023-05-02", "completion_date": "2025-10-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-11-15T18:42:32.043Z", "location_count": 20, "location_summary": "Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05639751" } ] }